Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer

Clinical Cancer Research

Volumn 22, Issue 9, 2016, Pages 2283-2289

  Iyengar, Neil M ^a,b   Zhou, Xi Kathy ^b   Gucalp, Ayca ^a,b   Morris, Patrick G ^a   Howe, Louise R ^b   Giri, Dilip D ^a   Morrow, Monica ^a   Wang, Hanhan ^b   Pollak, Michael ^c   Jones, Lee W ^a,b   Hudis, Clifford A ^a,b   Dannenberg, Andrew J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AROMATASE INHIBITOR; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIACYLGLYCEROL;

ADIPOCYTE; ADULT; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROGNOSIS; PROGNOSTIC ASSESSMENT; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; SOFT TISSUE INFLAMMATION; TRIPLE NEGATIVE BREAST CANCER; WHITE ADIPOSE TISSUE; AGED; BREAST; BREAST TUMOR; COMPLICATION; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ADULT; AGED; BREAST; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; INTERLEUKIN-6; LEPTIN; MACROPHAGES; METABOLIC SYNDROME; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84968739477     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2239     Document Type: Article

References (50)

1. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013;19:6074-83.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
4. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book 2013:46-51.
5. Iyengar NM, Morris PG, Hudis CA, Dannenberg AJ. Obesity, Inflammation, and Breast Cancer. In:Dannenberg AJ, Berger NA, editors. Obesity, Inflammation, and Cancer. New York, NY: Springer; 2013. p. 181-217.
6. Levi J, Segal LM, St. Laurent R, Lang A, Rayburn J. F as in Fat: How Obesity Threatens America's Future 2012. 2012 [cited 2012 Sep 28]. Available from: http://healthyamericans.org/assets/files/TFAH2012FasInFatFnlRv.pdf.
7. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med 2015;66:297-309.
8. Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004;23:6365-78.
9. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15: 556-65.
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
11. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25-31.
12. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;2010:23.
13. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002;13:325-32.
14. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111:329-42.
15. Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 2015;33: 2353-60.
16. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-46.
17. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 2014;156:20-44.
18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
19. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010;2010:Article ID 289645.
20. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat 2014;147:159-65.
21. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol 2014;32:3568-74.
22. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
23. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 2011;29:54-60.
24. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
25. Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri D, Harbus MD, et al. Menopause is a determinant of breast adipose inflammation. Cancer Prev Res 2015;8:349-58.
26. Sun X, Casbas-Hernandez P, Bigelow C, Makowski L, Joseph Jerry D, Smith Schneider S, et al. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat 2012;131:1003-12.
27. NCCN. NCCN Clinical Practice Guidelines in Oncology v.2.2011; 2011. Available from: www.nccn.org.
28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
29. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25: 2127-32.
30. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
31. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011;4: 329-46.
32. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29:32-9.
33. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-64.
34. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003;88:1721-6.
35. Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, et al. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One 2014;9:e111306.
36. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
37. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 2012;30:164-71.
38. Xu XJ, Gauthier MS, Hess DT, Apovian CM, Cacicedo JM, Gokce N, et al. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res 2012;53:792-801.
39. Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299: E506-15.
40. Denis GV, Obin MS. Metabolically healthy obesity': origins and implications. Mol Aspects Med 2013;34:59-70.
41. Chen S, Chen Y, Liu X, Li M, Wu B, Li Y, et al. Insulin resistance and metabolic syndrome in normal-weight individuals. Endocrine 2014;46: 496-504.
42. Deepa M, Papita M, Nazir A, Anjana RM, Ali MK, Narayan KM, et al. Lean people with dysglycemia have a worse metabolic profile than centrally obese people without dysglycemia. Diabetes Technol Ther 2014;16:91-6.
43. Arendt LM, McCready J, Keller PJ, Baker DD, Naber SP, Seewaldt V, et al. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 2013;73:6080-93.
44. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 2008;98:370-9.
45. Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. Cancer Res 2015;75:2375-86.
46. Nakayama S, Miyoshi Y, Ishihara H, Noguchi S. Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 2008;112:405-10.
47. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010;21:610-8.
48. Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia 2013;18:277-89.
49. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70:741-51.
50. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, et al. Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 2015;107(3)djv006.